Literature DB >> 34154791

Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.

Viola W Zhu1, Shannon S Zhang2, Jian Zhang3, Jeffrey Swensen3, Joanne Xiu3, Sai-Hong Ignatius Ou4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34154791     DOI： 10.1016/j.jtho.2021.03.006

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

Review 1.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

2.  Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.

Authors:  Toshio Fujino; Kenichi Suda; Takamasa Koga; Akira Hamada; Shuta Ohara; Masato Chiba; Masaki Shimoji; Toshiki Takemoto; Junichi Soh; Tetsuya Mitsudomi
Journal:  J Hematol Oncol       Date:  2022-06-11       Impact factor: 23.168

Review 3.  Precision therapy for RET-altered cancers with RET inhibitors.

Authors:  Kyaw Z Thein; Vamsidhar Velcheti; Blaine H M Mooers; Jie Wu; Vivek Subbiah
Journal:  Trends Cancer       Date:  2021-08-12

4.  Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.

Authors:  Shannon S Zhang; Sai-Hong Ignatius Ou
Journal:  JTO Clin Res Rep       Date:  2022-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.